Prostatic Adenocarcinoma Clinical Trial
Official title:
Prediction of the Risk of Biochemical Relapse After Radical Prostatectomy for Prostate Cancer Using Radomics on Pre-therapeutic MRI
With 50% of post-operative biochemical failure, efficient predictive models are needed to
guide post-operative management.
Radiomic features are quantitative features extracted from medical imaging, supposed to be
correlated with tumor heterogeneity.
We aim to build and test three predictive models (clinical, radiomic and combined models).
n/a
| Status | Clinical Trial | Phase | |
|---|---|---|---|
| Completed |
NCT01431391 -
Sequencing of Sipuleucel-T and ADT in Men With Non-metastatic Prostate Cancer
|
Phase 2 | |
| Not yet recruiting |
NCT06015321 -
An Open Label Phase II Study of First-Line Maintenance Enzalutamide Following Docetaxel Plus Androgen-Deprivation Therapy in Patients With Previously-Untreated, Metastatic, Castration-Naive Prostatic Adenocarcinoma
|
Phase 2 | |
| Completed |
NCT03384199 -
Dose Escalation Using Fiducial Markers in Image Guided Volumetric Modulated Arc Therapy to the Focal Lesion Micro Boost of Localized Prostate Cancer
|
Phase 2 | |
| Completed |
NCT02361515 -
Hypofractionated Radiotherapy Versus Stereotactic Irradiation With Hyaluronic Acid
|
N/A | |
| Active, not recruiting |
NCT01542021 -
Androgen Deprivation Therapy Prior to Prostatectomy for Patients With Intermediate and High Risk Prostate Cancer
|
N/A | |
| Recruiting |
NCT05498272 -
Study of Neoadjuvant PARP Inhibition Followed by Radical Prostatectomy in Patients With Unfavorable Intermediate-Risk or High-Risk Prostate Cancer With BRCA1/2 Gene Alterations
|
Phase 2 |